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INVESTIGATIONS conceming the possible localization of radio-active-labeled
dyes in tumors have show-n that some of these compounds tend to concentrate
in vital organs to a greater extent than in cancerous tissue. Thus Br82 and I131
derivatives of Evans Blue andTrypan Blue, when administered to tumor-bearing
mice, localized in the neoplasm to a greater extent than in skeletal muscle or
skin, but considerably less than in liver, spleen or kidneys (Moore, Tobin and
Aub, 1943 ; Stevens, L'ee, Stewart, Quinlin and Gilson, 1949).
If a compound could be found which would display a greater affinity for the
tumor than for such vital organs as the liver and kidneys, whfle at the same time
maintaining a favorable ratio of concentrations in tumor and surrounding tissue,
it wouldgreatly increase the chances of accuratediagnosis andtherapy ofinternal
cancer.
Several characteristics of the sulfonamido linkage endow sulfonamides with
diagnostic andtherapeuticpotentialities. So far as couldbe found intheliterature,
the work ofRay and Argus (1951) describes the only case of in vivo hydrolysis of
a sulfonamido linkage and this hydrolysis occurred to the extent ofonly 0-5 per
cent. The azo linkage which occurs in Evans Blue and Trypan Blue is quite
susceptible to enzymatic fission. In addition to locahzing in certain tissues
(Bloch, Schiff, Fleming, Shapiro and Steinberg, 1945 ; Stevens, Quinlin, Meinken
and Kock, 1950), sulfonamides have been show-n to reduce the effective vitamin
intake ofanimalsbysuppressing the intestinalflora, and this reduction ofessential
vitamins in the diet of tumor-bearing mice is known to inhibit the growth of
tumors (Boyland, 1938). Ray and Soffer (1950) proposed the incorporation of S35
into thesecompounds. Thisshort-range beta emitter would notonly exertpossible
additional therapeutic effects, but would also offer a means of detection.
Recent distribution studies in tumor-bearing mice with disodium fluorene-2,7-
disulfonate-S35 (Argus, 1953) revealed that the ratios of locahzation in tumor
tissue compared to the liver, kidneys, spleen, blood and muscle for this compound
were greatly increased over similar values obtained for dyes. Thus this fluorene
compound offered a promising basis upon which to build sulfonamido derivatives
for localization studies. In the present study, therefore, the following compounds
were prepared: fluorene-2,7-disulfo'amide-S35 (I) ; n fluorene-2,7-di-(sulfonamido-
2 -naphthalene)-S35 (II) ; and a sulfonated derivative offluorene-2,7-di-(sulfona-
mido-2'-naphthalene)-S35 (III). In addition to following the distribution of each
of these sulfonamides in tumor-bearing mice, Compound II was also studied
i
control (non-tumor) mice and in tumor mice previously injected with glucose.
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to 6-4, primarily because of the formation of lactic acid (Kahler and Robertson,
1943). Ray and Soffer (1950) have suggested that injection of glucose prior to
the administration of a sulfonamide might, by lowering the pH in the tumor,
-suppress the ionization of an acidic sulfonamide, thus reducing its solubility and
forcing its deposition in the cancer tissue.
MATERIALS AND METHODS.
Fluorene-2)7-disulfonyl chloride-S35.-Fluorene, 16-6 g. (0-1 moles), was added
slowly. (20 minutes) with stirring to 36-6 ml. (0-6 moles), chlorosulfonic acid
containing 5 to 8 millicuries Sulfur-35. After 4 hours standing at room tempera-
ture, the reaction mixture was centrifuged and the precipitate collected, washed
free of acid with cold water, and air dried. Recrystallization from toluene gave
6-6 g. of product melting 215-218'; further purification brought the melting
point to 225-2260, but suchpurity- was not necessary for thesubsequent reactions ;
Courtot and Geoffroy (1924) report 225-2260 for fluorene-2,7-disulfonyl chloride.
Fluorene-2)7-disulfonamide_S35 (I).-Fluorene-2,7-disulfonyl chloride- S3-1,3-8 9..
was dissolved in 125 ml. chloroform and the solution wasgassed withdry ammonia
until the gas ceased to be absorbed. The reaction mixture was allowed to stand
8 hours at 50, after which the white precipitate was collected, washed free of
ammonium chloride with water, washed with 20 ml. hot 95 per cent ethanol, and
air-dried. The yield was 2-3 g. or 64 per cent oftheory; the compound had a
specific activity of 64,000 counts per minute per mg. and melted on the block at
3140 ; Courtot P930) gives amelting point of 3150 forfluorene-2,7-disulfonamide.
Fluorene-2)7-di-(sulfonamido-2'-naphthalene)-S35 (II).-Finely powdered fluor-
ene-2,7-disulfonyl chloride-S35, 5 g. (0-016 moles), was slowly added to a solution
of 2-naphthylamine, 8 g. (0-058 moles), in 130 ml. benzene. The solution was
stirred and maintained at 55' throughout the addition (20 minutes) and for an
additional 2 hours, after which the reaction mixture was aRowed to cool to room
temperature and the precipitate coHected. Evaporation of the filtrate to 120 ml.
gave additional product. The combined precipitates were washed free of 2-
naphthylamine hydrochloride with water and air dried. Recrystallization from
95 per cent ethanol gave 2-7 g. (34-8 per cent oftheory) of white product melting
at 223-224' and having a specific activity of 27,000 counts per minute per mg. A-nalysis gave 11-68 per cent S, 69-21 and 69-43 per cent C, 4-70 and 4-73 per
cent H, and 4-45 and 4-64 per cent N; the calculated values are 11-11 per cent
S, 68-75 per cent C, 4-16 per cent H, and 4-84 per cent N.
Sulfonated derivative offluorene-2,7-di-(sulfonamido-2'-naphthalene)-S35 (III).-
To fluorene-2.7-di-(sulfonamido-2'-naphthalene)-S-35, 0-5 g. (0-9 milhmoles), sus-
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(3-4 millimoles), in 5 ml. chloroform. The reaction mixture was allowed to stand
at room temperature for 40 minutes, after which the precipitate was collected,
washed with chloroform and air dried. This product was dissolved in 10 ml.
water and reprecipitated with an equal volume of saturated sodium acetate after
the pH of the water solution had been brought to 9 with concentrated sodium
hydroxide. The resultin-a 0-2 . ofproduct was dried over phosphorus pentoxide
and iised for the preliminary studies without analysis since it was difficult to
completely free the compound from sodium acetate. The material injected had
an activity of 20,000 counts per minute per mg.
Animal experiment8.
A subaxillary transplanted, keratinizing squamous cell carcinoma (Line A,
stomach carcinomata originally obtained from the Animal Supply and Research
Units of the British Empire Cancer Campaign) was employed. The fluorene
compounds were administered by tail vein injection when the tumors averaged
300 mg. in weight; the animals were sacrificed at 2-, 8- and 32-hour intervals
following injection. Pooled samples from 2 animals were used for each determina-
tion. The animals were etherized just prior to sacrifice and blood removed from
the aorta at the iliac bifurcation, using a heparinized syringe. The concentration
of radio-active material was determined in each of the following tissues : tumor,
liver, spleen, kidneys, stomach with contents, intestine with contents, leg muscle,
and subaxillary skin from the side opposite the tumor. Planchets ofthese samples
were prepared and counted as described previously (Argus, 1953).
The 30 mice used were 4 to 5 weeks old and were grouped as follows:
Group I : Six strain A/Jax, 48th generation tumor hosts, each receiving 5 mg.
fluorene-2,7-disulfonamide-S35 (1) in 0-5 ml. 0-15 N NaOH.
Group 11 : Eighteen CAF,/Jax hybrid mice each receiving 5 mg. fluorene-2,7-
di-(sulfonamido-2'-naphthalene)-S35 (IT) in 0-25 ml. 4 per cent sodium
bicarbonate containing 20 per cent ethanol.
Subgroup Ila Six 55th generation tumor hosts.
Subgroup Ilb Six 55th generation tumor hosts each administered intra-
peritoneally 120 mg. glucose in 0-1 ml. water, immediately prior to
receiving (11).
Subgroup llc: Six non-tumor mice.
Group III : Six CAF1/Jax hybrid mice, 55th generation tumor hosts, each
receiving 5 mg of the sulfonated derivation of fluorene-2,7-di-(sulfon-
amido-2'-naphthalene)-S35 (111) in 0-25 ml. water.
RESULTS AND DISCUSSION
The results of the distribution studies with fluorene disulfonamides are sum-
marized in Table I : Two hours after administration offluorene-2,7-disulfonamide-
S35 (Group I) the leg muscle had a higher concentration of the compound than did
the tumor. At 8 and 32 hours, however, localization in the neoplasm was slightly higher than in the muscle. At none of the time intervals studied did the tumor
concentrate more of the compoiind than did the liver, kidneys and spleen. These
findings are in contrast to those obtained previously with fluorene-2,7-disulfonate
which showed a more favorable localization in the tumor than in the vital organs (Argus, 1953).701 TUMOR LOCALIZATION WITH FLUORENE DERIVATIVES
TABLEI.-Distribution ofRadioactivity in Micefollowing Intravenous Injection of
Disulfonamido Derivatives of Fluorene.
Concentration in lig* compound Per cent administered radio-
per g. tissue or ml. blood. activity recovered.t
r A A.
---A - r tGroup Group Group Group Group Group Group Group Group Group
I. IIa. Ilb. IIc. III. 1. lIa. IIb. Ilc. III.
Two hours:
Tumor 88 22 14
Leg muscle 108 80 .64 92
Liver 1330 1620 1424 2004
Spleen 498 838 610 2028
Kidneys 543 528 384 360
Blood 330 221 - 489
Skin 60 70 56
Stomach with con-
tents 69 100 72 116
Small intestine with
contents 504 312 326 290
Total
108 0- 5
122
544 31- 9
224 1- 8
662 3- 6
974 8- 8
634
140 0- 5
906 13- 0
60- 1
156 0- 6
48
328 25
- 3
86 0- 1
236 6- 7
268 2- 9
288
138 0- 3
706 6- 3
42- 2
0- 2 0.1
30- 9 31- 3 46- 6
2- 0 1- 7 3
- 7
2
- 3 1.9 1.9
4- 9 13
- 0
0- 3 o-3 0- 5
6- 0 7
- 5 7- 1
46- 6 42
- 8 72- 8
0- 7 0.1
16-4 12- 8 26- 7
1- 2 0- 5 2
- 3
1
- 7 2-0 1- 5
13- 3 12- 0 3- 7
0- 4 0- 6 0- 6
8- 4 7
- 5 5- 6
42- 1 35- 5 40- 4
0- 7
8- 7
0- 6
2- 7
18
- 5
0- 7
16- 9
48- 8
1.1
5.6
0- 2
1.0
5- 8
0- 6
12- 5
26- 8
Eight hours:
Tumor 60
Leg muscle 52
Liver 1042
Spleen 360
Kidneys 1052
Blood 109
Skin
Stomach with con-
tents 36
Small intestine with
contents 282
Total
54
88
760
394
346
553
120
86
372
46
94 56
644 1288
220 1486
360 280
510 226
110 90
78 88
328 260
Thirty-two hours:
Tumor 30
Leg muscle 14
Liver 750
Spleen 397
Kidneys 762
Blood 45
Skin
Stomach with con-
tents 30
Small intestine with
contents 246
Total
0
10
142
3
28
38
42
48
52
4
0 0
74 186
0 28
6 20
22 23
24 32
18 16
20 38
90 0-2 0.0 <0.1 1.0
0
80 18-1 3.1 1-9 4-4 1-5
4 0-6 <0. 1 0.0 <0. 1 <0.1
36 5-6 0.2 <0.1 0-2 0-2
65 1-2 0.8 0-6 0-7 1-6
0
16 0-2 0.2 <0.1 0.1 <0.1
10 4-1 2-2 0-5 1.1 0-2
30-0 <6-6 <3-3 <6-6 <4-7
* Calculated on the assumption that the administered molecule remains intact.
t The per cent recovery is based on the analysis of 2 mice (10 mg. active compound). $ Group I, tumor mice receiving fluorene-2,7-disulfonamide-S35; Group II, mice receiving fluorene-2,7-di-(sulfamido-2'-naphthalene)-S35 (a, tumor mice; b, tumor mice previously injected withglucose ; c, non-tumormice) ; GroupIII, tumor micereceiving sulfonated derivative offluorene-
2,7-di-(sulfonamido-2'-naphthalene)-S35.
An even greater contrast was obtained with fluorene-2,7-di-(sulfonamido-2'-
naphthalene)_S35 (Group IIa). Here the concentration ofcompOund in the tumor
was at all times less than that found in any other tissue analysed. A comparison
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at the different time intervals showed a greater amount ofactivity in the blood
at 8 hours than at 2 hours. Since the compound was administered intravenously,
the data indicate a return to the blood of the compound or a metabolite at some
time after the initial uptake ofcompound from the blood.
The animals in Group Ilb, differed from those in Group IIa only in that the
former received anintraperitonealinjection ofglucose prior to the administration
of fluorene-2,7-di-(sulfonamido-2'-naphthalene)-S35. This was done i-n the hopes
ofimproving the localization ofradioactivecompound in the tumor, bydecreasing
the pH of this tissue. A comparison of the data in Table I for these two groups,
however, does not reveal any substantial differences in the distribution of radio-
activity. Thus, if the pH of the neoplasm was decreased, the solubility of the
disulfonamide at the lowerpH was not sufficiently different from that at the usual
tumor pH to bring about increased localization.
Contrasts do exist between the distribution data for Group IIc and Group lIa,
indicating a difference in the metabolic process oftumor-bearing mice compared
to non-tumor-bearing mice receiving the same compound. The disulfonamide was
concentrated in the liver andspleen ofthe control animals (GroupIlc) to agreater
extent than in these organs in the mice with tumors at 2, 8, and 32 hours. The
concentration of radioactivity in the liver of the control mice at 8 hours was
almost twice that in the tumor-bearing mice, while the spleen of the controls
held over three times as much compound as did the spleen of the animals of
Group Ila. Although the spleens of the tumor hosts were slightly enlarged,
bistological examination did not reveal any pronounced differences in the livers
and spleens ofthe tumor mice compared with those of control mice. The contrast
in localization of labeled disulfonamide which exists indicates that the presence
of a tumor in the animal body has affected some mechanism in these vital organs.
Since, in the present study, this.difference could be measured while no changes
were evident microscopically, a possible diagnostic tool is suggested.
Comparing the blood data for Group Ila and Group llc, the values for the
non-tumor animals present a more reasonable picture inasmuch as the highest
activity was found at 2 hours followed by successively decreasing concentrations
at the longer time intervals. The total amount of compound accounted for at 2
hours in the control mice was significantly greater than that found in tumor-
bearing mice at the same time (72-8 per cent ofthe administered dose as compared
to 46-6 per cent). This increased recovery for the animals ofGroup lIc was due
chiefly to the greater concentrations in the liver, spleen and blood. At 8 and 32
hours no particular difference in the total recovery existed.
In the present study the best results with respect to tumor localization were
obtained with the sulfonated derivative of fluorene-2 7-di-(sulfonamido-2
naphthalene)-S35(GroupIII). At each time-period studied a greater concentration
ofthis compound was found in tumor tissue than for the other compounds tested.
For the animals ofGroup 111, the localization in the tumor tissue at 8 hours was
greater than that in theleg muscle andspleen, while at 32 hours the concentration
of radioactive compound in the neoplasm was greater than that in any of the
tissues analysed. These data, together with those obtained previously with
fluorene-2,7-disulfonic acid (Argus, 1953), suggest that the presence of sulfonic
acid groups in a molecule offers a better chance for tumor localization.
Favorable locahzation appears to be due in part to the solubihty of the com-
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of the compound from the animal body. Chemical studies revealed fluorene-2,7-
di-(sulfonamido-2'-naphthalene)-S-35 to possess a slightly greater solubility than
fluorene-2,7-di-sulfonamide-S'-15 (Group 1). In Ene with this, at 32 hours the total
amount ofcompound accounted for in animals receiving the' naphthalene deriva-
tive was substantially greater than that found in the animals of Group 1. The
even more soluble sulfonic acid compound (Group III) was eliniinated most
rapidly, the difference in total amount remaining in the animals be'mg marked
as early as 8 hours.
The size ofthe molecule is also to be considered. The sulfonic acidinvestigated in the presentstudy (GroupIII) was a muchlarger molecule than thefluorene-2,7- disulfonic acid studied previously (Argus, 1953). Inasmuch as increasing the
molecular weight did not increase tumor locahzation, the authors feel that an
aromatic sulfonic acid oflesser molecular weight than fluorene-2,7-disulfonic acid
should be investigated.
SUMMARY.
Syntheses are described for fluorene-2,7-disulfonamide-S'15 J) ; fluorene-2,7- di-(sulfonamido-2'-naphthalene)-S35 (II); and a sulfonated derivative offluorene-
2,7-di-(sulfonamido-2'-naphthalene)-S'-15 (III). The distribution ofradioactivity in
the tissues of tumor-bearing mice following a single injection of each of these
compounds was stuclied at 2-, 8-, and 32-hour intervals. In addition, Compound (H) was also traced in non-tumor mice and in tumor mice previously injected with glucose. Differences in the metabohc process oftumor-bearing and tumor-
free mice were suggested. The most favorable tumor localization was obtained
with the sulfonated derivative.
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